|
Nov. 08, 2024 |
|
|
Oct. 06, 2025 |
|
|
jRCT2031240474 |
39-301: Special Drug Use-Results Survey of DEMSER (Improvement of catecholamine hypersecretion in pheochromocytoma) |
|
39-301: Special Drug Use-Results Survey of DEMSER |
Nakao Takafumi |
||
Ono Pharmaceutical Co.,LTD |
||
1 -5 Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, Japan |
||
+81-6-6222-5501 |
||
pms_contact_ml@ono-pharma.com |
||
Nakao Takafumi |
||
Ono Pharmaceutical Co.,LTD |
||
1 -5 Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, Japan |
||
+81-6-6222-5501 |
||
pms_contact_ml@ono-pharma.com |
Recruiting |
Feb. 26, 2019 |
||
| June. 11, 2019 | ||
| 250 | ||
Observational |
||
single arm study |
||
open(masking not used) |
||
uncontrolled control |
||
single assignment |
||
other |
||
Patients who have recieved DEMSER for improvement of catecholamine hypersecretion in pheochromocytoma |
||
none |
||
| No limit | ||
| No limit | ||
Both |
||
Pheochromocytoma |
||
Safety items : Occurrence of adverse drug reactions and infections, factors considered to influence the safety |
||
| Ono Pharmaceutical Co.,LTD |
| Not being included in the items required by GPSP Ordinance, a central IRB is not in place. The study is planned to conduct an IRB at the study site as needed. | |
| none, Kanagawa | |
April. 17, 2019 |
No |
none |